

FOI REF: 25/121

23rd February 2025

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions:

- 1) How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

• Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	38
• Abemaciclib + Fulvestrant	0
• Alpelisib + Fulvestrant	3
• Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	0
• Aromatase Inhibitor as a single agent	0
• Atezolizumab	0
• Capecitabine as a single agent	34
• Carboplatin + Paclitaxel	4
• Elacestrant	0
• Eribulin as a single agent or in combination	3
• Everolimus + Exemestane	1
• Fulvestrant as a single agent	0
• Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	24
• Palbociclib + Fulvestrant	4
• Parp Inhibitors (Olaparib/Talazoparib)	0
• Pembrolizumab	5
• Pertuzumab (Perteja) + Trastuzumab (Herceptin)	3
• Phesgo (Pertuzumab + Trastuzumab in a single injection)	39
• Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	38
• Ribociclib + Fulvestrant	17

Cont.../

•	Sacituzumab Govitecan	5
•	Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	44
•	Trastuzumab deruxtecan (Enhertu)	7
•	Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	31
•	Trastuzumab emtansine (Kadcyla)	7
•	Any other active systemic anti-cancer therapy	58

- 2) How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies:

•	Phesgo (Pertuzumab + Trastuzumab in a single injection)	11
•	Pertuzumab (Perteja) + Trastuzumab (Herceptin)	1
•	Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	6
•	Trastuzumab deruxtecan (Enhertu)	5
•	Trastuzumab emtansine (Kadcyla)	6

- 3) If breast cancer is not treated at or within the Trust, where are patients referred?

Not applicable.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net